The Cystic Fibrosis Foundation announced a new set of research agreements to drive progress on its Path to a Cure. The nine awards will advance a variety of tools and strategies to accelerate treatments for the underlying cause of cystic fibrosis for all people with CF, regardless of their mutations.
Today, the Cystic Fibrosis Foundation awarded $2.76 million for 11 laboratory studies that will advance our understanding of the underlying factors that impact COVID-19 outcomes in people with cystic fibrosis. Ultimately, insights gained from this body of research may be used to improve future treatments.
Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.
Potential oral formulation of drug targeting nontuberculous mycobacteria infections could reduce side effects of current treatment
Potential treatment from Calithera Biosciences minimizes growth of germs in the lungs
Today, the Cystic Fibrosis Foundation announced that it awarded funding to enGene Inc. to develop a customized vehicle to deliver genetic-based therapies, such as gene therapy and gene editing, into the lung cells of people with cystic fibrosis (CF). Delivering genetic-based therapies to the lungs is a key hurdle to developing effective treatments for all people with CF, including individuals with two nonsense and rare mutations.
Nonprofit commits $20 million to fund projects and accelerate genetic therapies for CF
The Cystic Fibrosis Foundation announced the recipients of its fifth annual Impact Grants.
Study reaffirms the Foundation's commitment to advance solutions to the growing challenge of antibiotic resistance and evaluate the use of phage to treat infections for people with CF